Ferumoxytol four Phase III clinical trials results positive
Date from more than four Phase III clinical trials of AMAG Pharmaceuticals’ IV iron replacement therapy ferumoxytol have demonstrated positive efficacy and safety results. Aggregate data for three studies showed a significantly greater mean hemoglobin increase from the base line to the 35th day in patients who received ferumoxytol, as compared to those who received oral iron.
- Spectrum Pharmaceuticals completes enrollment in Phase III bladder cancer trial
- Prevention Of Organ Rejection In Stable Kidney Transplant Patients – LCP-Tacro™ Moves Into Clinical Phase 3
- Quark Pharmaceuticals Poised To Advance Clinical Studies Of QPI 1002
- KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism
